Project Grant SB1NS079060

This $427,625 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the University of Washington aims to develop and optimize two novel blood-based biomarker assays to improve clinical diagnosis and differential diagnosis of Parkinson's disease (PD) and multiple system atrophy (MSA). The key products and services to be delivered under this 2-year grant include: Further development and optimization of a flow cytometry-based assay (APOGEE) to directly quantify...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports the development of a blood-based biomarker for characterizing disease progression and therapeutic response in amyotrophic lateral sclerosis (ALS). The awardee, Neurodex Inc., a small for-profit organization, is advancing the validation of an assay for measuring...

Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $446,991 to the University of California, Los Angeles under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on August 7, 2025, with completion scheduled for July 31, 2027. This Project Grant supports the development of a novel diagnostic assay for identifying parkinsonian tauopathies, specifically progressive supranuclear palsy...

This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $320,143 to Mayo Clinic to assess the diagnostic and disease biomarker utility of blood plasma measures in patients with atypical Alzheimer's disease (AD). The 2-year project aims to determine if plasma biomarkers can differentiate atypical AD patients from healthy controls and other clinical syndromes, as well as evaluate if the plasma biomarkers correlate with clinical...

The National Institute on Aging (NIA) awarded a $459,250 Project Grant (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate and validate the use of dried blood spot (DBS) samples for measuring Alzheimer's disease (AD) biomarkers. The key objectives are to: 1) optimize fingerstick collection methods and validate assays for three key AD biomarkers (pTau217, GFAP, and NFL) in DBS samples; 2) establish if DBS...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $238,500 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, San Diego (UCSD) to develop a novel electrochemical lateral flow assay (ELFA) for diagnosing tuberculosis (TB) from a single drop of blood. The objective is to create a highly sensitive and specific point-of-need TB detection test that can accurately distinguish active TB from...

L2 Diagnostics LLC received a $293,142 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 21, 2025, with a completion date of August 31, 2027. The award supports development of a rapid diagnostic test (RDT) in lateral flow assay (LFA) format for detecting Babesia microti infection. The test targets BMGPI12 (BMSA1), a secreted protein released into the...

Federal Grant Award Summary Meganano Diagnostics Inc. received a $483,346 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop an RT-qPCR (reverse transcription quantitative polymerase chain reaction) assay for early diagnosis of Alzheimer's disease (AD). The award was obligated on September 15, 2025, with an ultimate completion date of August 31, 2026. The research builds on preliminary findings demonstrating that T cell...

Summary: Mechanisms of ALS/FTD Determined by Multimodal Single Cell Spatial Transcriptomics The University of California, San Diego received a $3.08M Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded September 12, 2025, with a completion date of June 30, 2029. This research grant funds the development and application of a multimodal spatial...